Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
- Amanda Psyrri(corresponding author),
- Aris Bamias,
- Ziwei Yu,
- Paul M. Weinberger,
- Mohamad Kassar,
- Sophia Markakis
- Yale Cancer Center,
- Yale University,
- National and Kapodistrian University of Athens
Open access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
Purpose: p27 protein is regarded as a valuable prognostic biomarker in cancer with a potential use as a molecular target. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of p27 in ovarian cancer using a novel method of compartmentalized in situ protein analysis. Experimental Design: A tissue array composed of 150 advanced stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of p27 protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis [automated quantitative analysis (AQUA)]. Results: The mean follow-up time of the patients was 34.3 months. Patients with low Fédération Internationale des Gynaecologistes et Obstetristes stage were more likely to have low nuclear p27 expression (P = 0.008). Low nuclear p27 expression was associated with improved 3-year overall survival (66% versus 20%, P = 0.0047) and disease-free survival (27% versus 12%, P = 0.022). In multivariable analysis, adjusting for well-characterized prognostic variables, low nuclear p27 expression level was the most significant prognostic factor for both disease-free and overall survival. Conclusions: Our results indicate that quantitative assessment of nuclear p27 expression level by automated in situ quantitative analysis is a strong predictor for outcome in ovarian cancer.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 8384-8390 (7 pages)Journal (Volume, Issue Number)
Clinical Cancer Research (Volume 11, Issue 23)Publication milestones
- Published - 12/01/2005
Publication status
ISSN
1078-0432Publication IDs
- Scopus: 28544433273
- PubMed: 16322299
